A Phase I/II Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 02 May 2011
At a glance
- Drugs Dasatinib; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 02 May 2011 Planned End Date changed from 1 Dec 2010 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 17 Sep 2010 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.